3,5-二甲基-4-氨基苯甲酰胺 | 103796-44-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二甲基-4-氨基苯甲酰胺
• 中文别名: 4-氨基-3,5-二甲基苯甲酰胺
• 英文名称: 4-Amino-3,5-dimethylbenzamide
• CAS: 103796-44-7
• 化学式: C₉H₁₂N₂O
• mdl: MFCD07369842
• 分子量: 164.2
• InChiKey: GHFMYUFOFXWGBF-UHFFFAOYSA-N

物化性质

• 沸点：
  272.9±40.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310,P305+P351+P338
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H319

文献信息

• [EN] PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRIDONÉAMIDE EN TANT QU'INHIBITEURS DE LA KINASE D'ADHÉSION FOCALE (FAK) ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009024332A1

  公开（公告）日：2009-02-26

  Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式(I)的化合物及其药用盐、对映体形式、二对映异构体和混合物，上述化合物的制备，含有它们的药物以及它们的制造，以及上述化合物在控制或预防癌症等疾病中的用途。
• [EN] BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] ACIDES BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIQUES, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018077699A1

  公开（公告）日：2018-05-03

  The present invention relates to compounds of general formula (I) wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula (I).

  本发明涉及一般式(I)的化合物，其中团R、R1、R2、R3、m和n的定义如权利要求书中所述，该化合物具有有价值的药理特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。此外，本发明涉及用于合成一般式(I)化合物的新中间体。
• Ionic Liquids for Separation of Olefin-Paraffin Mixtures
  申请人：Dai Sheng

  公开号：US20110015461A1

  公开（公告）日：2011-01-20

  The invention is directed to an ionic liquid comprising (i) a cationic portion containing a complex of a silver (I) ion and one or more neutral ligands selected from organoamides, organoamines, olefins, and organonitriles, and (ii) an anionic portion having the chemical formula wherein m and n are independently 0 or an integer of 1 or above, and p is 0 or 1, provided that when p is 0, the group —N—SO 2 —(CF 2 ) n CF 3 subtended by p is replaced with an oxide atom connected to the shown sulfur atom. The invention is also directed to a method for separating an olefin from an olefin-paraffin mixture by passing the mixture through a layer of the ionic liquid described above.

  该发明涉及一种离子液体，包括（i）含有银（I）离子的阳离子部分，该离子与来自有机酰胺、有机胺、烯烃和有机腈中选择的一个或多个中性配体形成的络合物，以及（ii）具有化学式的阴离子部分，其中m和n独立地为0或大于1的整数，p为0或1，但当p为0时，由p支撑的基团—N—SO2—(CF2)nCF3将被连接到所示硫原子的氧原子替代。该发明还涉及一种从烯烃烷烃混合物中分离烯烃的方法，通过将混合物经过上述离子液体的一层来实现。
• [EN] BENZYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] ACIDES BENZYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIQUES, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018138028A1

  公开（公告）日：2018-08-02

  The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式（I）的化合物，其中R，R1，R2，R3，m和n的定义如权利要求书中所述，具有有价值的药理特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受该受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。
• Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP2065380A1

  公开（公告）日：2009-06-03

  Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的目的是式 I 的化合物 它们的药学上可接受的盐、对映体、非对映异构体和外消旋体，上述化合物的制备方法，含有上述化合物的药物及其制造方法，以及上述化合物在控制或预防癌症等疾病中的用途。